[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569135":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":55,"collaborators":25,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":25,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Affiliated Hospital of Nantong University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"sulfentanil group","ACTIVE_COMPARATOR","Participants in the active comparator group will receive sulfentanil for PCIA.",[13],"Procedure: patient controlled intravenous analgesia(PCIA)",{"label":15,"type":16,"description":17,"interventionNames":18},"oxycodone group","EXPERIMENTAL","Participants in the experimental group will receive oxycodone for PCIA.",[13],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","patient controlled intravenous analgesia(PCIA)","Patients will receive sulfentanil for PCIA.",[9],null,{"type":21,"name":22,"description":27,"armGroupLabels":28,"otherNames":25},"Patients will receive oxycodone for PCIA.",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Siyuan Liu, PhD","CONTACT","+86-85050301","tdfylsy@ntu.edu.cn",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Affiliated hospital of Nantong University","RECRUITING","Nantong","Jiangsu","226001","China","CN",{"type":45,"coordinates":46},"Point",[47,48],120.87472,32.03028,{"lat":48,"lon":47},[51],{"name":52,"role":32,"phone":53,"phoneExt":25,"email":54},"Wei Shi","0513-85052297","jsrdwbb@126.com",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Siyuan Liu","Principal Investigator","100569135","phase-4-oxycodone-versus-sufentanil-in-patient-controlled-intravenous-analgesia-after-laparoscopic-hysterectomy-100569135",false,"NCT06690307","Oxycodone Versus Sufentanil in Patient-controlled Intravenous Analgesia After Laparoscopic Hysterectomy","The Efficacy and Safety of Oxycodone in Patient-controlled Intravenous Analgesia After Laparoscopic Hysterectomy","Oxycodone","Inclusion Criteria:\n\n* selective laparoscopic hysterectomy\n* general anesthesia\n* ASA classification I - III\n* aged 18 - 65 years\n\nExclusion Criteria:\n\n* allergy to oxycodone or any other drugs will be used in the study\n* preoperative opioids medication\n* opioids abuse\n* hepatic or renal dysfunction\n* cardiovascular or pulmonary dysfunction\n* lack of full civil capacity or refuse to participate","FEMALE","18 Years","65 Years",{"count":71,"type":72},64,"ESTIMATED","INTERVENTIONAL",[75],"PHASE4","This study is designed to evaluate the efficacy and safety of hydrocodone in patient-controlled intravenous analgesia (PCIA) during gynecological laparoscopy, thus to explore suitable PCIA scheme to optimize postoperative pain management for patients undergoing gynecological laparoscopic surgeries.",[78],"Laparoscopic Hysterectomy",[80,81,82],"oxycodone","patient-controlled intravenous analgesia","laparoscopic hysterectomy","2024-12-02",{"date":85,"type":86},"2024-12-04","ACTUAL",{"date":88,"type":86},"2024-12-03",{"date":90,"type":72},"2026-07-31",{"name":5,"class":6},1]